{'fraction_non_alphanumeric': 0.028346456692913385, 'fraction_numerical': 0.025196850393700787, 'mean_word_length': 6.571428571428571, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Presentations at the annual meeting of The Finnish Society for Rheumatology, Helsinki, 25–26 January 2007

Presentations at the annual meeting of The Finnish Society for Rheumatology, Helsinki, 25–26 January 2007 INFLIXIMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHROPATHIES IN CLINICAL PRACTICE: REASONS FOR DISCONTINUATION AND SERIOUS ADVERSE EVENTS T Levälampi, M Korpela, K Vuolteenaho, E Moilanen. The Immunopharmacology Research Group, Medical School, University of Tampere and Tampere University Hospital, Finland, and Department of Internal Medicine, Section of Rheumatology, Tampere University Hospital,